The Royal Brompton and Harefield Hospitals have now been accredited to provide Transcatheter Aortic Valve Implantation (TAVI) procedures for Bupa members. Royal Brompton Hospital performed over 350 TAVI procedures last year which is the most of any single centre in the UK. Having been accredited to the Bupa TAVI network, this number looks to grow even higher in coming years.
Why is TAVI so revolutionary?
For those suffering from aortic stenosis or aortic regurgitation, one of the only options in the past for treatment was open heart surgery to replace the valves that are failing. An alternative, less invasive form of aortic valve replacement may now be offered, whereby a new aortic valve can be implanted under the skin either via the arteries in the groin, the arm, directly into the aorta or via a small cut in the chest. Since none of these methods require the breast bone to be cut or open heart surgery to be performed, they are less traumatic than conventional surgical aortic valve replacement.
The stent with the valve inside is inserted into the body through the tube in either the leg, arm vessel, or directly into the aorta, over the diseased valve. The cardiologist will then expand the new valve open over the old aortic valve. The old valve will therefore not be removed but will be used to anchor the new valve in place. The stent will stay in place for the rest of the patient’s life and should not cause any problems.
Typically patients leave the hospital between five and ten days after the procedure. This procedure should cure aortic stenosis, so reducing the risk of heart failure and any shortness of breath, chest pain or fainting.
Royal Brompton Hospital Success
Clinicians at The Royal Brompton Hospital have implanted the most TAVI devices of all UK centres, with over 350 devices successfully completed to date. The transcatheter team at the Royal Brompton Hospital is composed of a world-class team of Consultant Cardiologists, Cardiac Surgeons, and Cardiac Imagers, led by the Programme Director, Mr. Neil Moat. The clinical team work in close relationship with leading members of industry, to ensure that The Royal Brompton TAVI programme remains a driving force in the clinical and research development of this exciting new treatment for severe aortic valve disease.